Dynamic contrast-enhanced micro-CT on mice with mammary carcinoma for the assessment of antiangiogenic therapy response.

Objective: To evaluate the potential of in vivo dynamic contrast-enhanced micro-computed tomography (DCE micro-CT) for the assessment of antiangiogenic drug therapy response of mice with mammary carcinoma.Methods: 20 female mice with implanted MCF7 tumours were split into control group and therapy g...

Descripción completa

Detalles Bibliográficos
Publicado en:European Radiology Vol. 22; no. 4; pp. 900 - 908
Autores principales: Eisa F, Brauweiler R, Hupfer M, Nowak T, Lotz L, Hoffmann I, Wachter D, Dittrich R, Beckmann MW, Jost G, Pietsch H, Kalender WA, Eisa, Fabian, Brauweiler, Robert, Hupfer, Martin, Nowak, Tristan, Lotz, Laura, Hoffmann, Inge, Wachter, David, Dittrich, Ralf
Formato: research Journal Article
Publicado: Springer Nature Apr2012
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104534362&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104534362
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09387994
        NPH
      jtl: European Radiology
      issn: 09387994
      maglogo: N
    pubinfo:
      dt: Apr2012
      vid: 22
      iid: 4
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        104534362
        NLM22071777
        2011490202
        10.1007/s00330-011-2318-9
        NLM22071777
        104534362
      ppf: 900
      ppct: 8
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Dynamic contrast-enhanced micro-CT on mice with mammary carcinoma for the assessment of antiangiogenic therapy response.
      aug:
        au:
          Eisa F
          Brauweiler R
          Hupfer M
          Nowak T
          Lotz L
          Hoffmann I
          Wachter D
          Dittrich R
          Beckmann MW
          Jost G
          Pietsch H
          Kalender WA
          Eisa, Fabian
          Brauweiler, Robert
          Hupfer, Martin
          Nowak, Tristan
          Lotz, Laura
          Hoffmann, Inge
          Wachter, David
          Dittrich, Ralf
        affil: Institute of Medical Physics, University of Erlangen-Nuremberg, Henkest. 91, 91052, Erlangen, Germany
      sug:
        subj:
          Angiogenesis Inhibitors Administration and Dosage
          Breast Neoplasms Drug Therapy
          Breast Neoplasms Radiography
          Contrast Media
          Diagnostic Imaging
          Sirolimus Analogs and Derivatives
          Tomography, X-Ray Computed
          Animal Studies
          Cells
          Female
          Mice
          Reproducibility of Results
          Sensitivity and Specificity
          Sirolimus Administration and Dosage
          Tomography, X-Ray Computed Methods
          Treatment Outcomes
          Female
      ab: Objective: To evaluate the potential of in vivo dynamic contrast-enhanced micro-computed tomography (DCE micro-CT) for the assessment of antiangiogenic drug therapy response of mice with mammary carcinoma.Methods: 20 female mice with implanted MCF7 tumours were split into control group and therapy group treated with a known effective antiangiogenic drug. All mice underwent DCE micro-CT for the 3D analysis of functional parameters (relative blood volume [rBV], vascular permeability [K], area under the time-enhancement curve [AUC]) and morphology. All parameters were determined for total, peripheral and central tumour volumes of interest (VOIs). Immunohistochemistry was performed to characterise tumour vascularisation. 3D dose distributions were determined.Results: The mean AUCs were significantly lower in therapy with P values of 0.012, 0.007 and 0.023 for total, peripheral and central tumour VOIs. K and rBV showed significant differences for the peripheral (P(per)(K) = 0.032, P(per) (rBV) = 0.029), but not for the total and central tumour VOIs (P(total)(K) = 0.108, P(central)(K) = 0.246, P(total) (rBV) = 0.093, P(central) (rBV) = 0.136). Mean tumour volume was significantly smaller in therapy (P (in vivo) = 0.001, P (ex vivo) = 0.005). Histology revealed greater vascularisation in the controls and central tumour necrosis. Doses ranged from 150 to 300 mGy.Conclusions: This study indicates the great potential of DCE micro-CT for early in vivo assessment of antiangiogenic drug therapy response.Key Points: Dynamic contrast enhanced micro-CT (computed tomography) is a new experimental laboratory technique. DCE micro-CT allows early in vivo assessment of antiangiogenic drug therapy response. Pharmaceutical drugs can be tested before translation to clinical practice. Both morphological and functional parameters can be obtained using DCE micro-CT. Antiangiogenic effects can be visualised with DCE micro-CT.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N